Efficacy and Safety of Altibrain^® as an Adjunctive Therapy for Autism Spectrum Disorder: An Open Label Trial Targeting Core Symptoms.

ABSTRACT:

Objective

This study aimed to evaluate the effectiveness and safety of Altibrain^® in combination with standard Autism Spectrum Disorder (ASD) treatment compared to standard ASD treatment alone in individuals diagnosed with ASD.

Methods

A randomized, open-label trial was conducted involving 120 participants aged 3 to 17 years, randomly assigned to either the Standard ASD Treatment group or the Altibrain^® + Standard ASD Treatment group. Sixty patients were randomly allocated to each Standard ASD Treatment group or the Altibrain^® + Standard ASD Treatment group. Participant allocation was done by computer-generated randomization. Participants had confirmed ASD diagnoses based on DSM-V or ICD-11 criteria and demonstrated moderate to severe core AS

SUBMITTER: Mehan S 

PROVIDER: S-EPMC12307958 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature